Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENOM: Venetoclax with Obinutuzumab and Magrolimab in Indolent B-cell Malignancies
NCT04599634Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and 2 more (4 arms), sponsored by National Cancer Institute. Primary endpoint: Dose-limiting Toxicities at 5 weeks. Started Dec 2021; status: completed.
02
Drugs
venetoclax
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04599634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599634.